PLYMOUTH MEETING, PA — New research published in the July 2025 issue of JNCCN—Journal of the National Comprehensive Cancer Network offers encouraging news for men diagnosed with nonmetastatic prostate ...

The National Comprehensive Cancer Network ® (NCCN ®)-an alliance of leading cancer centers-has published a new book explaining the latest evidence and expert recommendations around prostate cancer ...

People with localized prostate cancer treated according to guidelines developed by an international panel of doctors are more likely to die of something other than the disease, new research shows. A ...

It does if a single state in the U.S. is any indication. In North Carolina, significantly higher rates of prostate cancer recurrence were reported among men living in rural areas compared to their ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...

Patients with nonmetastatic prostate cancer are more likely to die from other causes than from cancer when treated per guidelines. The 15-year cancer mortality risk is 5.5% for low-risk and 22% for ...

PLYMOUTH MEETING, PA [April 28, 2026] — The National Comprehensive Cancer Network ® (NCCN ®)—an alliance of leading cancer centers—has published a new book explaining the latest evidence and expert ...

The National Comprehensive Cancer Network (NCCN) has expanded two cancer genetic risk assessment guidelines to meet the growing understanding of hereditary cancer risk and use of genetic tests in ...

SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and tumor genomic testing, commends the updated Prostate Cancer Guidelines from the National ...